Merck & Co., Inc. Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount
Merck & Co., Inc. (MRK) reported Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount of $111.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Debt and Equity Securities › Equity Securities without Readily Determinable Fair Value, Annual Amount
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount · last filed 2026-08-07
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2026-03-31 was $35.00M.
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2024-03-31 was $4.00M, a 300.00% increase year-over-year.
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2023-03-31 was $1.00M, a 92.86% decline year-over-year.
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for the quarter ending 2022-03-31 was $14.00M, a 57.58% decline year-over-year.
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2025 was $3.00M, a 84.21% decline from fiscal 2024.
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2024 was $19.00M, a 90.00% increase from fiscal 2023.
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2023 was $10.00M, a 82.14% decline from fiscal 2022.
- Merck & Co., Inc. equity securities without readily determinable fair value, upward price adjustment, annual amount for fiscal 2022 was $56.00M, a 49.09% decline from fiscal 2021.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 6 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 9 month | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $111.00M 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | $35.00M 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $3.00M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $1.00M 10-Q · filed 2025-11-05 | |||
| 2024-12-31 | $19.00M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $12.00M 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $61.00M 10-Q · filed 2025-08-05 | |||
| 2024-03-31 | $4.00M 10-Q · filed 2025-05-02 | |||
| 2023-12-31 | $10.00M 10-K · filed 2025-02-25 | |||
| 2023-09-30 | $7.00M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $3.00M 10-Q · filed 2024-08-05 | |||
| 2023-03-31 | $1.00M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $56.00M 10-K · filed 2024-02-26 | |||
| 2022-09-30 | $21.00M 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | $20.00M 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $14.00M 10-Q · filed 2023-05-05 | |||
| 2021-12-31 | $110.00M 10-K · filed 2023-02-24 | |||
| 2021-09-30 | $104.00M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $75.00M 10-Q · filed 2022-08-05 | |||
| 2021-03-31 | $33.00M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $62.00M 10-K · filed 2022-02-25 | |||
| 2020-09-30 | $21.00M 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | $18.00M 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $20.00M 10-K · filed 2021-02-25 | |||
| 2019-09-30 | $4.00M 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $4.00M 10-Q · filed 2020-08-05 | |||
| 2018-12-31 | $167.00M 10-K · filed 2020-02-26 | |||
| 2018-09-30 | $199.00M 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $129.00M 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |